Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764197 | 0.87 | PDE3B (0.39) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL4044221 | 0.82 | PDE3B (0.39) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL4034400 | 0.81 | PDE3B (0.39) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL28904650 | 0.77 | MAPT (0.51) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL30026033 | 0.77 | MAPT (0.51) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL3306255 | 0.76 | PDE3B (0.43) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL3306252 | 0.76 | PDE3B (0.43) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL10030181 | 0.76 | L3MBTL1 (0.55) | PDE3BPDE3AP2RY12ALDH1A1L3MBTL1 | |
| SCHEMBL3300820 | 0.75 | PDE3B (0.42) | PDE3BPDE3AP2RY12HTTAPP | |
| SCHEMBL27774508 | 0.74 | MAPT (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653109-B2 | Substituted bipyridine derivatives and their use as adenosine receptor ligands | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| EP-2066637-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | Bayer HealthCare AG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028590-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028590-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093728-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | PDE3B 508/4885PDE3A 519/4885P2RY12 41/4885 |
| US-20140155401-A1 | NOVEL SUBSTITUTED BIPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | PDE3B 508/4885PDE3A 519/4885P2RY12 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.